制药 是本所业务分支,下属于 生命科学.
突破性的发现和创新需要强有力的保护
人类对制药行业寄予厚望,希望他们研制出挽救生命的新药和改善生活质量的治疗方法。但是,即使投入数十亿美元的研发资金,实际能通过临床试验和监管机构严格的上市批准程序的药物却寥寥无几。因此,新药一旦成功上市,公司必须采取措施,保护与新药及治疗方法有关的知识产权。飞翰长期与富有创新精神的制药企业合作,协助他们保护和充分利用自己宝贵的知识产权资产,制定申办路径策略与专利组合规划。
精通法律、科学与技术
飞翰客户的业务和知识产权资产遍布全球,在各司法管辖区保护资产的挑战性日益上升。飞翰在世界各地设有代表处,经常与跨国企业合作,拥有必要的资源与经验,能够协助制药企业制定和执行全球策略。由于新发明及其商业应用的迅速发展,律师事务所必须全面掌握与知识产权有关的法律问题,并具备相关行业视野与见解,才能理解与这类发展有关的科学与策略问题。
我们具有为制药客户处理过几乎所有类型知识产权问题的经验,协助企业:
我们与客户在众多领域合作、创新、推进科学,包括:
In a rare rehearing proceeding, successfully represented petitioner Incyte in an inter partes review (IPR) challenging the validity of Concert’s patent before the Patent Trial and Appeal Board (PTAB). Continued representation of appellee Incyte before the Federal Circuit and secured a unanimous affirmance of the PTAB’s obviousness determination.
IPR2017-01256, PTAB, Judges Fitzpatrick, Hulse, Yang, Smith, Franklin
19-2011, Fed. Cir., Judges Hughs, Linn, Stark
2:23-cv-00094, 2:23-cv-02364, D.N.J., Judges Cecchi, Padin, Wettre
IPR2022-01200, PGR2022-00051, PTAB, Judges Newman, Snedden, Wisz
22-2232, Fed. Cir.
PGR2022-00037, PTAB, Judges Newman, Obermann, Worth
IPR2022-00738, -00739, -00796, PTAB, Judges Cotta, Wisz, Worth
1:21-cv-10954, D. Mass., Judge Burroughs
1:21-cv-02258, 1:21-cv-02899, N.D. Ill., Judge Lee
Workshop
Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law
May 2, 2024
Cambridge
Workshop
Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law
May 2, 2024
Cambridge
Award/Ranking
Five Finnegan Partners Named 2024 Leading Litigators in America by Lawdragon
October 30, 2023
Commentary
Behind the Case: How Finnegan Helped Eli Lilly Swerve a $176.5M Patent Headache
October 10, 2023
Award/Ranking
Finnegan Shortlisted in 10 Categories in the LMG Life Sciences Awards 2023
July 25, 2023
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.